logo

For the Inventor, By the Inventor

New York, NY, United States of America

Intra-cellular Therapies, Inc.


USPTO Granted Patents = 172



Trademarks = 13

Forward Citations = 3,310

Loading Chart...
Loading Chart...

67 inventors (with patents filed for the assignee):

goldMedal Peng Li (132 out of 148 patents)

silverMedal Lawrence P Wennogle (98 out of 98 patents)

bronzeMedal Robert E Davis (72 out of 144 patents)

4.  Sharon Mates (37 out of 37 patents)

5.  Qiang Zhang (29 out of 31 patents)

6.  Kimberly Vanover (24 out of 24 patents)

7.  Hailin Zheng (24 out of 24 patents)

8.  Jun Zhao (24 out of 26 patents)

9.  Wei Yao (22 out of 24 patents)

10.  John Charles Tomesch (21 out of 24 patents)

11.  Gretchen Snyder (19 out of 19 patents)

12.  Allen Fienberg (12 out of 12 patents)

13.  Andrew S Thompson (10 out of 75 patents)

14.  James David Beard (9 out of 14 patents)

15.  Hua Cheng (9 out of 9 patents)


Core Competencies:
Central Nervous System Disorders
Lumateperone
Pharmaceutical Compositions
Organic Compounds
Transmucosal Methods
Gamma-Carbolines
Acute Depression
Nitric Oxide Donors
Amorphous Solid Dispersions
Cardiotoxicity
Heterocycle Fused Compounds
Psychiatric Conditions

172 patents:

1. 12478623 - Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor (2025-11-25),
2. 12472178 - Amorphous solid dispersions (2025-11-18),
3. 12465570 - Methods (2025-11-11),
4. 12440489 - Organic compounds (2025-10-14),
5. 12435093 - Free base crystals (2025-10-07),
6. 12414948 - Methods (2025-09-16),
7. 12410195 - Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders (2025-09-09),
8. 12410175 - Compounds (2025-09-09),
9. 12409176 - Methods of treating acute depression (2025-09-09),
10. 12396992 - Organic compounds (2025-08-26),
11. 12384783 - Salts and crystals (2025-08-12),
12. 12364695 - Methods of treating inflammatory disease (2025-07-22),
13. 12364694 - Organic compounds (2025-07-22),
14. 12358916 - Substituted heterocycle fused gamma-carbolines synthesis (2025-07-15),
15. 12336989 - Transmucosal methods for treating psychiatric and neurological conditions (2025-06-24),
Intra-Cellular Therapies, Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative medicines to treat central nervous system (CNS) disorders. The company's mission is to address unmet medical needs and improve the lives of patients suffering from mental health disorders. Through their proprietary technology, they develop novel therapeutics that target specific pathways within the CNS. Intra-Cellular Therapies is committed to advancing scientific research and bringing transformative treatments to people in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

172 Patents

#65 in New York, NY

#135 in New York

#2,251 in US

#4,684 in the World

...
New York, NY, United States of America

Intra-cellular Therapies, Inc.

Forward Citations = 3,310

67 inventors:

goldMedal Peng Li (132 out of 148 patents)

silverMedal Lawrence P Wennogle (98 out of 98 patents)

bronzeMedal Robert E Davis (72 out of 144 patents)

4.  Sharon Mates (37 out of 37 patents)

5.  Qiang Zhang (29 out of 31 patents)

Please report any incorrect information to support@idiyas.com
Loading…